Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369549 | 0.86 | PNMT (0.55) | HRH3PNMTKMT2ADRD2DRD1 | |
| SCHEMBL13450138 | 0.84 | SIGMAR1 (0.50) | HRH3DRD2CYP2C19 | |
| SCHEMBL18376160 | 0.84 | HTR2C (0.50) | HRH3PNMTHTR2CKMT2ADRD2 | |
| SCHEMBL12681593 | 0.82 | PRMT5 (0.41) | HRH3KMT2ACARM1PRMT6PRMT1 | |
| SCHEMBL12681586 | 0.82 | CARM1 (0.44) | KMT2ACARM1PRMT6PRMT1PRMT5 | |
| SCHEMBL6369525 | 0.81 | CARM1 (0.59) | HRH3PNMTCARM1PRMT6PRMT1 | |
| SCHEMBL13171916 | 0.81 | HRH3 (0.51) | HRH3PNMTHTR2CKMT2ACARM1 | |
| SCHEMBL21216375 | 0.81 | HRH3 (0.51) | HRH3PNMTCARM1PRMT6PRMT1 | |
| SCHEMBL30238474 | 0.81 | HRH3 (0.51) | HRH3PNMTCARM1PRMT6PRMT1 | |
| SCHEMBL6369712 | 0.81 | HRH3 (0.54) | HRH3PNMTKMT2ACARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016144703-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-8173672-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009117283-A2 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | HRH3 107/4885PNMT 470/4885HTR2C 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.